Salts, Crystal Forms, and Production Methods Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 62/710,416, filed Feb 16, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,815,249 | Salts, Crystal Forms, and Production Methods Thereof In force · High confidence UsedRemaining | Sunovion Pharmaceuticals Inc. | In force | High confidence | ||
| US 11,440,921 | Salts, Crystal Forms, and Production Methods Thereof In force · High confidence | Sunovion Pharmaceuticals Inc. | In force | High confidence | ||
| US 11,987,591 | Salts, Crystal Forms, and Production Methods Thereof In force · Medium confidence | Sumitomo Pharma America, Inc. | In force | Medium confidence | ||
| Application 18/636,653 | Salts, Crystal Forms, and Production Methods Thereof Abandoned Abandoned Nov 18, 2025 | Sumitomo Pharma America, Inc. | Abandoned | Abandoned Nov 18, 2025 | ||
| Application 19/257,755 | Salts, Crystal Forms, and Production Methods Thereof Pending Not granted | Sumitomo Pharma America, Inc. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Sunovion Pharmaceuticals Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.